focus -WSS

focus

author：leisure time 2025-09-27 12:54:48 - browse：6

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Akili changes sales model for its ADHD video game treatment

WSS

Information blocking fines are now fair game in health care

DIEP, the 'gold standard' of breast reconstruction, is under threat

The unintended consequences of overturning Roe v. Wade

Medicare proposal to cover medical devices draws a mixed reaction

Why the quest to eradicate polio has stumbled

Fed up with FDA, ALS advocates consider a take

knowledge

focus

focus

Continuity nursing helped my family in our darkest PICU moments

Heart attack and stroke risk calculators need revising

Bright Health sells Medicare Advantage business to Molina

Fed up with FDA, ALS advocates consider a take

In age of alternative facts, a scholarly course on calling out crap

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Bright Health sells Medicare Advantage business to Molina

ChatGPT in medicine: STAT answers readers' burning questions

At least 13 dead in Texas as scorching temps continue

Hepatitis C has a cure — but many Americans still lack access to it

entertainment

Free Covid tests will again be offered to all U.S. households

Why the quest to eradicate polio has stumbled

FDA panel to weigh safety of artificial wombs for preterm births

White House Covid adviser calls on docs to combat misinformation

Virginia high school admissions case could be legal follow

Covid’s new normal has set in amid another rise in cases

entertainment

knowledge

hotspot

Wikipedia